MBRS-50. PEROXIREDOXIN1 IS A THERAPEUTIC TARGET IN GROUP-3 MEDULLOBLASTOMA

Group-3 medulloblastoma (MBL) is highly resistant to radiation (IR) and chemotherapy and has the worst prognosis. Hence, there is an urgent need to elucidate targets that sensitize these tumors to chemotherapy and IR. Employing standard assays for viability and sensitization to IR, we identified PRD...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Sajesh, Babu, On, Ngoc, Omar, Refaat, Fediuk, Holly, Li, Lin, Alrushaid, Samaa, Wang, W, Pu, J, Sun, H D, Siahaan, Teruna, Werbowetski-Ogilvie, Tamra, Wolfl, Matthias, Remke, Marc, Ramaswamy, Vijay, Taylor, Michael, Eberehart, Charles, Symons, Marc, Ruggieri, Rosa Maria, Miller, Donald, Vanan, Issai
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2018
Matèries:
Abstracts
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6012188/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy059.495
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars